trending Market Intelligence /marketintelligence/en/news-insights/trending/HCVuqCFxkBgHV6z2RvF9Pw2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Predilife raises €3.6M in IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Predilife raises €3.6M in IPO

Predilife SA has raised about €3.6 million in gross proceeds from its IPO on the Euronext Growth Paris market.

The Paris-based biotechnology company issued 386,154 shares through an open-price offering and a simultaneous global placement for €9.30 apiece. The share price was at the lower end of the price range that was previously set at €8.76 to €11.84.

Predilife's shares will start trading on the Euronext Growth Paris market on Dec. 21 under the symbol ALPRE.

The company plans to use the proceeds for the commercialization of MammoRisk, an imaging tool for assessing breast cancer risk. Predilife will also use the amount raised in the IPO for repayment of loans to Bpifrance.

Stéphane Ragusa is the chariman and CEO of Predilife, a company that uses statistical data to develop mathematical models for risk profiling of individuals regarding the occurrence of serious diseases.